| Literature DB >> 35268246 |
Krixie Silangcruz1, Yoshito Nishimura1,2, Torrey Czech1, Nobuhiko Kimura1, James Yess1.
Abstract
Serum procalcitonin (PCT) has been reported as a potential biomarker to predict the severity of acute cholangitis (AC) or the need for urgent biliary decompression. This study aimed to identify and summarize the existing research about serum PCT and the severity of AC, and to find gaps towards which future studies can be targeted. Following the PRISMA extension for scoping reviews, MEDLINE, EMBASE, and Google Scholar were searched for all peer-reviewed articles with relevant keywords including "cholangitis" and "procalcitonin" from their inception to 13 July 2021. We identified six studies. All the studies employed a case-control design and aimed to evaluate the usefulness of serum PCT to predict the severity of AC with key identified outcomes. While the potential cut-off values of serum PCT for severe AC ranged from 1.8-3.1 ng/mL, studies used different severity criteria and the definition of urgent biliary decompression. No studies proposed cut-off PCT values for the need for urgent biliary decompression. This scoping review identified the current level of evidence regarding the usefulness of serum PCT in assessing the severity of AC. Further clinical research is warranted with a focus on standardized outcome measures employing prospective or experimental designs.Entities:
Keywords: acute cholangitis; procalcitonin; scoping review; systematic review
Year: 2022 PMID: 35268246 PMCID: PMC8910914 DOI: 10.3390/jcm11051155
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure 1PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flowchart of the search strategy.
Main characteristics of the included studies in the scoping reviews.
| Author, Year, | Study Type | Aim | Outcome | Population | Comparative Groups | Key Findings | Limitations |
|---|---|---|---|---|---|---|---|
| Hamano et al., 2013 Japan [ | CC | To evaluate the usefulness of PCT for AC severity assessment | Serum PCT value | Severe AC | Mild ( | PCT was significantly higher in patients with severe AC than those with mild or moderate ( | No cut-off for early/urgent biliary drainage. |
| Shinya et al., 2014 Japan [ | CC | To evaluate the correlation of AC severity and serum PCT | Serum PCT value | Severe AC | Mild ( | PCT was significantly higher in patients with severe AC than those with mild AC ( | All included patients had AC due to choledocholithiasis |
| Umefune et al., 2017, Japan [ | CC | To evaluate the correlation between serum PCT on admission and severity of AC | AC severity | Severe AC | Mild ( | Patients with multiple causes of AC included ( | Small sample size to limit the robustness of secondary analyses |
| Lee et al., 2018, South Korea [ | CC | To determine the association of serum PCT with AC severity and clinical deterioration | Positive blood culture | Severe AC | Mild ( | PCT was significantly higher in patients with severe AC than those with mild or moderate ( | Considerable portion of patients with malignant stricture ( |
| Lyu et al., 2014, China [ | CC | To evaluate the role of PCT to assess the severity of AC | Serum PCT value | Severe AC | Mild ( | PCT was significantly higher in patients with severe AC than those with mild or moderate ( | Retrospective data from a single center |
| Korekawa et al., | CC | To evaluate the usefulness of PCT to diagnose AC, and to determine a management plan | Serum PCT value | Severe AC | Mild ( | PCT was significantly higher in patients with severe AC than those with mild or moderate ( | Only seven severe AC patients were included |
Abbreviations: AC, acute cholangitis; CC, case control; ERCP, endoscopic retrograde cholangiopancreatography; IQR, interquartile range; PCT, procalcitonin; TG, Tokyo Guidelines.
Key findings related to serum procalcitonin levels in the included studies.
| Author, Year, | Severity Criteria Used | PCT–Median (ng/mL) | Cut-Off PCT for Urgent Biliary Decompression | Cut-Off PCT for Severe AC (ng/mL) | AU-ROC of PCT | Comments | ||
|---|---|---|---|---|---|---|---|---|
| Mild AC | Moderate AC | Severe AC | ||||||
| Hamano et al., 2013 Japan [ | TG07 | 0.08 | 0.37 | 5.56 | N/A | 3.1; sensitivity 80.8%, specificity 84.6%, OR 23.1 [95%CI 8.0–70.2] | Severe vs. mild to moderate | N/A |
| Shinya et al., | TG13 | 0.2 (IQR; 0.1–0.7) | 0.7 (IQR; 0.2–2.7) | 6.8 (IQR; 0.5–48.3) | N/A | 2.33; sensitivity 64.0%, specificity 78.0% | Severe AC | Median PCT of those with purulent bile juice: 7.9 ng/mL (IQR; 1.2–37.7) vs. 0.6 (IQR; 0.2–2.9) in those with normal bile juice |
| Umefune et al., | TG13 | 0.45 | 1.25 | 19.51 | N/A | 2.2; sensitivity 97.0%, specificity 73.0% | Severe AC | Median PCT of those with positive blood culture: 4.71 ng/mL (IQR, 0.87–16.96) vs. 0.65 ng/mL (IQR, 0.25–2.26) in those with negative blood culture |
| Lee et al., 2018, South Korea [ | TG13 | 0.22 | 1.35 | 9.41 | N/A | 1.76 (for severe AC or septic shock); sensitivity 84.6%, specificity 62.4% | Severe vs. mild to moderate | Median PCT of those with positive blood culture: 3.25 ng/mL (IQR, 8.86) vs. 0.62 ng/mL (IQR, 3.78) in those with negative blood culture |
| Lyu et al., 2014, China [ | TG13 | 0.166 (mean; SD ± 0.033) | 0.349 (mean; SD ± 0.046) | 0.759 (mean; SD ± 0.029) | N/A | 2.38 (for severe vs. moderate AC); sensitivity 78.9%, specificity 73.7% | N/A | N/A |
| Korekawa et al., | TG13 | 0.9 | 9.9 | 37.8 | N/A | N/A | Severe and moderate vs. mild | Median PCT of those with positive blood culture: 12.7 ng/mL (IQR, 0.45–19.8) vs. 4.6 ng/mL (IQR, 0.2–4.9) in those with negative blood culture |
Abbreviations: AC, acute cholangitis; AU-ROC, area under the receiver operator characteristic; CI, confidence interval; CRP, C-reactive protein; DIC, disseminated intravascular coagulopathy; IQR, interquartile range; OR, odds ratio; PCT, procalcitonin; SD, standard deviation; TG, Tokyo Guidelines; WBC, white blood cell.